Careful analysis for difficult decisions
With escalating health care costs, it is important that every dollar improves patient outcomes as much as possible. Australia's system of funding healthcare technologies is at the forefront of this effort.
For medicines seeking reimbursement, legislation was introduced in 1987 requiring consideration of cost and effectiveness. In 1993, Australia was the first country to require an economic evaluation. This has stimulated development of similar systems worldwide.Today, economic evidence is essential when deciding which medicines and medical services Australia will fund and at what price.
Monash Evaluation Group
The Monash Evaluation Group at the Centre for Health Economics has been integral to decisions made by Australia's Medical Services Advisory Committee (MSAC) and Pharmaceutical Benefits Advisory Committee (PBAC) since the start of external evaluation by independent academic groups.
We have evaluated hundreds of technologies, for MSAC since 1999 and since 2001 for PBAC.
Under the leadership of Associate Professor Silva Zavarsek, our multidisciplinary team includes:
- Jing Jing Li
- Peter Ghijben
- Francis Ip
- Karen Yong
- Yee Ching Ng
We conduct precise and thorough evaluations of:
- clinical and economic data provided by sponsors of pharmaceuticals and medical services
- assessment of the clinical and cost-effectiveness of medical technologies, including development of modelled economic evaluations
- reviews of listed medicines or technologies to ensure continued value for money.
Completed reviews have led to significant price reductions to listed drugs, resulting in millions of dollars in savings to the health budget.